Drug Profile
Research programme: estrogen-related receptor alpha modulators - Galapagos
Alternative Names: ERR1 - GalapagosLatest Information Update: 28 Oct 2010
Price :
$50
*
At a glance
- Originator ProStrakan
- Class
- Mechanism of Action ERRalpha estrogen-related receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Osteoporosis
Most Recent Events
- 28 Oct 2010 Discontinued - Preclinical for Osteoporosis in France (unspecified route)
- 22 Dec 2006 Galapagos NV acquires ProStrakan's drug discovery unit
- 27 May 2005 Preclinical trials in Osteoporosis in France (unspecified route)